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Aims Intravascular inﬂammatory events during ischaemia/reperfusion injury following coronary angio-
plasty alter and denudate the endothelium of its natural anticoagulant heparan sulfate proteoglycan
(HSPG) layer, contributing to myocardial tissue damage. We propose that locally targeted cytoprotec-
tion of ischaemic myocardium with the glycosaminoglycan analogue dextran sulfate (DXS, MW 5000)
may protect damaged tissue from reperfusion injury by functional restoration of HSPG.
Methods and results In a closed chest porcine model of acute myocardial ischaemia/reperfusion injury
(60 min ischaemia, 120 min reperfusion), DXS was administered intracoronarily into the area at risk
5 min prior to reperfusion. Despite similar areas at risk in both groups (39+ 8% and 42+ 9% of left
ventricular mass), DXS signiﬁcantly decreased myocardial infarct size from 61+ 12% of the area at
risk for vehicle controls to 39+ 14%. Cardioprotection correlated with reduced cardiac enzyme
release creatine kinase (CK-MB, troponin-I). DXS abrogated myocardial complement deposition and
substantially decreased vascular expression of pro-coagulant tissue factor in ischaemic myocardium.
DXS binding, detected using ﬂuorescein-labelled agent, localized to ischaemically damaged blood
vessels/myocardium and correlated with reduced vascular staining of HSPG.
Conclusion The signiﬁcant cardioprotection obtained through targeted cytoprotection of ischaemic
tissue prior to reperfusion in this model of acute myocardial infarction suggests a possible role for
the local modulation of vascular inﬂammation by glycosaminoglycan analogues as a novel therapy to
reduce reperfusion injury.
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Introduction
Restoration of coronary blood ﬂow after a period of pro-
longed ischaemia is a double-edged sword. Although reper-
fusion by means of thrombolysis or percutaneous coronary
intervention (PCI) is critical for tissue salvage, it aggravates
ischaemic damage and instigates ischaemia/reperfusion
(I/R) injury.1 Evidence suggests an important role for the
complement system and its interactions with the endothelium
in the pathogenesis of this type of tissue damage.2,3
Reperfusion greatly accelerates ischaemia-induced comp-
lement activation and deposition.4 The membrane attack
complex directly stimulates synthesis of radical oxygen
metabolites5 and promotes adhesion of neutrophils to the
endothelium,6 and complement inhibition attenuates ischa-
emic tissue injury.7,8 In the clinical setting, complement
inhibition using anti-C5 antibody treatment leads to a survi-
val beneﬁt after PCI.9
Upon reperfusion after a prolonged period of ischaemia,
the affected endothelium takes on a pro-coagulant and pro-
inﬂammatory phenotype, with upregulation of pro-coagulant
tissue factor (TF) and vascular adhesion molecules, as well as
stimulation of cytokine production.10–12 Importantly, reperfu-
sion appears to be critical for injury to the luminal surface
coating of the endothelium, the glycocalyx.13,14 Indeed, inhi-
bition of glycocalyx modiﬁcations upon reperfusion attenu-
ates I/R damage.15 The glycocalyx, composed of a layer of
glycoproteins, proteoglycans, and associated glycosaminogly-
cans, serves as a barrier to transvascular exchange of macro-
molecules and leukocyte adhesion16,17 and regulates the
anticoagulant and anti-inﬂammatory properties of the endo-
thelium by enhancing the activity of TF pathway inhibitor
and antithrombin.18,19
In the current investigation, we studied the potential of
low molecular weight dextran sulfate (DXS, MW 5000) to
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attenuate I/R injury in vivo. DXS, a sulfated polysaccharide
and glycosaminoglycan analogue, inhibits the alternative,
classical, and lectin complement pathways20–22 as well as
the coagulation cascade.23 Furthermore, in vitro work in
our laboratory has shown that DXS inhibits complement-
mediated endothelial damage following cleavage of luminal
HSPGs by heparinase.22 For the current study, therefore,
our working hypothesis was that cytoprotection targeted to
ischaemically damaged endothelium and myocardium by
DXS may attenuate tissue injury in acute myocardial infarc-
tion through modiﬁcation of the local vascular environment.
Methods
Care and use of animals in the present study were in compliance
with the Guide for the Care and Use of Laboratory Animals (NIH
Publication No. 85-23, revised 1996).
Experimental model
Twenty large white pigs (30+ 2 kg) were pre-medicated with
Ketamin/Xylazin, Midazolam, and Atropin, intubated, and mechani-
cally ventilated with a Draeger respirator (O2/N2O 1:3, Isoﬂurane
1–1.5 vol.%). Central venous and arterial lines were introduced
and a single bolus of unfractionated heparin (2500 IU) administered
intravenously. Baseline values were recorded during a 30-min pre-
ischaemic period.
The left anterior descending (LAD) artery was occluded just
distally of the ﬁrst diagonal branch with a semi-compliant over-
the-wire PCI catheter (Concerto, Occam, the Netherlands; balloon
length 10 mm, diameter 2.5–3 mm). The balloon was inﬂated to
completely occlude the vessel (EncoreTM 26 inﬂation device,
Boston Scientiﬁc, Ireland; used pressure 4–6 atm) for 60 min.
Localization of the balloon and state of inﬂation was controlled
angiographically on a regular basis.
The 60-min ischaemia period was followed by 2 h of reperfusion.
Five minutes prior to reperfusion, 10 mL of DXS (MW 5000, Sigma
Chemical Co., St Louis, MO, USA; 25 mg/mL—this dose was chosen
after extensive previous experience and in vitro and in vivo
testing, n ¼ 7) or phosphate-buffered saline (PBS, vehicle control,
n ¼ 9) was injected intracoronarily through the tip of the catheter
into the area at risk (AAR) over a period of 2 min. After 3 min, the
balloon was deﬂated to allow 2 h of reperfusion. After the reperfu-
sion period, the balloon was re-inﬂated and 60 mL Evan’s Blue
injected intravenously. The animals were then sacriﬁced (intravenous
bolus potassium chloride) and the heart excised for further analysis.
In four further experiments, ﬂuorescein-labelled DXS (DXS-Fluo)
was used instead of the normal, unlabelled substance. DXS-Fluo,
possessing nearly identical biochemical properties as the unlabelled
substance, was produced using ﬂuorescein cadaverine (Molecular
Probes Europe, Leiden, The Netherlands) as described earlier.22
Heart, lungs, liver, kidneys, and spleen were retrieved and tissue
samples snap-frozen in Tissue-Tek OCT compound (Sakura Finetek
Europe BV, Zoeterwoude, The Netherlands). These samples were
used to analyse tissue distribution and binding of DXS.
ECG, mean arterial pressure (MAP), and left ventricular end-
diastolic pressure (LVEDP) were recorded throughout with a
Hewlett-Packard CMS patient monitor. Ejection fraction (EF) was
determined angiographically and calculated using the area-length
method according to Dodge.24
The experimenters, including the pathologists performing sub-
sequent staining and histological/immunochemical analysis, were
blinded with regard to treatment regimen. Randomization of the
animals into two groups was done prior to the beginning of the
experimental series, using a randomization code (PBS control
animals ¼ 0, DXS animals ¼ 1) created by a random number
generator (SAS, version 9.1.2, SAS Institute Inc., Cary, NC, USA).
The 10 mL samples (PBS or DXS solution) were prepared according
to the output of the randomization and stored at 2208C until use.
Randomization and sample preparation was performed by an
independent laboratory technician. Before pre-medication, the
corresponding vial was allocated to the pig (sequential number of
vial ¼ sequential number of the pig). All the 20 consecutively
enlisted pigs were treated according to the aforementioned proto-
col. There were no dropouts throughout the entire procedure in
any of the experiments. Sample size was determined from previous
in vitro and in vivo work as well as experience, but not by formal
sample size calculations.
In the case of ventricular ﬁbrillation, a biphasic deﬁbrillator
(150 J) was used for cardioconversion.
Infarct size
The AAR was determined at the end of the experiment through
LAD re-occlusion and intravenous injection of 60 mL Evan’s Blue
(2% wt/vol. solution), leaving all but the AAR stained blue. The
left ventricle was cut perpendicular to the septum from the apex
to the base into 3 mm slices. Viable myocardium [viable ischaemic
tissue (VIT)] from the AAR was stained bright red by incubating
the slices in 1% triphenyl tetrazolium chloride (TTC, Sigma, pH
7.4) for 20 min at 378C. The tetrazolium dye forms a dark-red for-
mazan complex in the presence of viable myocardium, which con-
tains active dehydrogenases and cofactors.25 Infarcted tissue
[necrotic ischaemic tissue (NIT)], however, remains unstained. The
VIT was separated from NIT. All three tissue sections [Evan’s Blue
positive area not at risk (ANR), NIT, and VIT] were weighed. By deﬁ-
nition, AAR is the sum of NIT and VIT. Data were expressed as total
left ventricular mass (LVM) in grams, AAR in grams, AAR as per cent
of LVM, NIT in grams, and NIT as per cent of AAR.
Complement and coagulation
Peripheral venous blood samples were collected (EDTA plasma/
serum), kept on ice until centrifugation (1750 g for 10 min at 48C),
and stored at –708C until further analysis.
Classical pathway complement activity was determined by stan-
dard CH50 assay with antibody-coated sheep erythrocytes.26 As a
global parameter for the coagulation system, activated partial
thromboplastin time (aPTT) was measured using Dade Actin FS
reagent in a standard coagulation assay.
Ischaemic markers
The levels of troponin I and creatine kinase (CK-MB fraction) were
determined by enzyme immunoassays (AxSYM microparticle enzyme
immunoassay platform, Abbott Laboratories, Abbott Park, IL, USA).
Both ELISAs were judged sensitive and speciﬁc for myocardial injury
in pigs. Neither of the two parameters showed elevated levels at
baseline or in healthy pigs.
Histology and immunostaining
Samples from ANR, NIT, and VIT were ﬁxed in 4% buffered formal-
dehyde, parafﬁn-embedded, cut into 3 mm sections, and stained
with haematoxylin-eosin for histological evaluation.
Five micrometre sections were cut from all snap-frozen tissue
samples, air-dried, acetone ﬁxed, hydrated, and labelled using a
two/three-step indirect immunoﬂuorescence technique. The anti-
bodies used were rabbit anti-human C1q, C3c/C3b, and C4c
(Dako); mouse monoclonal anti-human C7 (Quidel, Santa Clara,
CA, USA); and rat monoclonal anti-human HSPG (Abcam Limited,
Cambridge, UK). Cross-reactivity with the respective porcine anti-
gens was veriﬁed. Secondary antibodies were goat anti-rabbit
IgG(Hþ L)-FITC (Southern Biotechnology Associated, Birmingham,
AL, USA), rabbit anti-mouse Ig-FITC (Dako), and biotinylated goat
anti-rat IgG (Southern Biotechnology), followed by streptavidin-
FITC (Amersham Pharmacia Biotech). Immunohistochemical staining
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for TF with polyclonal rabbit anti-TF antibody was carried out as
reported previously.27,28
Statistics
Data from TTC staining (AAR/LVM and NIT/AAR in per cent) were
compared between groups by use of one-way analysis of variance
(ANOVA). Results for the DXS and PBS control groups for all other
parameters were compared by use of two-way repeated-measures
ANOVA with time and treatment as ﬁxed factors. Subject number
was included as random. Effects of interest were overall between-
group differences and interaction between group and time. The
assumption of the sphericity of our data was analysed by Mauchly’s
test and corrections were made where appropriate (Greenhouse-
Geisser). In the case of a signiﬁcant P-value in the overall ANOVA
with respect to between-group differences or group–time inter-
action, post-hoc analyses were performed. P-values were corrected
for multiple testing by Bonferroni correction. For all analyses,
P-values were two-sided and differences were considered to be
statistically signiﬁcant with a P-value of ,0.05. SAS Version 9.1.2
(SAS Institute Inc., Cary, NC, USA) and SPSS Version 12.0.1 (SPSS
Inc., Chicago, IL, USA) software were used for all analyses. Data,
unless otherwise speciﬁed, are presented as average+ standard
deviation in text and ﬁgures.
Results
Haemodynamic variables
During the experiments, there were no signiﬁcant diffe-
rences in MAP between the two groups (P ¼ 0.547 for
between-group differences, P ¼ 0.253 for group–time inter-
action). MAP dropped in both groups during late occlusion
and during the early reperfusion period (Figure 1A ). In
both groups, heart rate decreased during ischaemia and
increased again after the onset of reperfusion, with no sig-
niﬁcant differences noted (P ¼ 0.937 for between-group
differences, P ¼ 0.617 for group–time interaction,
Figure 1B ). Baseline LVEDP and the observed increase
during occlusion of the LAD were comparable in both
groups. LVEDP rapidly decreased upon restoration of coro-
nary blood ﬂow in both groups. Though not statistically sig-
niﬁcant, LVEDP showed better recovery in the DXS-treated
animals when compared with PBS controls until the end
of the 2 h reperfusion phase (P ¼ 0.190 for between-
group differences, P ¼ 0.456 for group–time interaction,
Figure 1C ). EF dropped during the 1 h ischaemia period in
both groups and did not substantially recover until the end
of the 2 h of reperfusion (P ¼ 0.731 for between-group
Figure 1 Monitoring of MAP (A ) and heart rate (B ) before occlusion (baseline), during early (ﬁrst half hour) and late (second half hour) ischaemia, and during
early (ﬁrst hour) and late (second hour) reperfusion phase. No signiﬁcant differences in MAP or heart rate between groups. LVEDP showed better recovery in the
DXS group during reperfusion, particularly in the ﬁrst hour (C ). Drop in EF during ischaemia, with no substantial recovery during 2 h of reperfusion and no sig-
niﬁcant inter-group differences (D ). Data are mean + standard deviation.
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differences, P ¼ 0.410 for group–time interaction,
Figure 1D ).
Soluble complement and coagulation parameters
Intracoronary DXS administration did not systemically inhibit
the classical complement pathway, as determined by CH50
test. CH50 baseline values were comparable in both groups.
No signiﬁcant changes were observed during the course of
the experiment (P ¼ 0.970 for between-group differences,
P ¼ 0.548 for group–time interaction, Figure 2A ).
DXS transiently inhibited the coagulation system with
prolongation of aPTT from 50+ 13 s during occlusion to
110+ 51 s at 5 min of reperfusion. Values normalized
again to 50+ 7 s at the 2 h point of reperfusion. No pro-
longation of aPTT was noted in the PBS control group
(P ¼ 0.098 for between-group differences, P ¼ 0.163 for
group–time interaction, Figure 2B ).
Plasma creatine kinase and troponin I
Cellular damage evaluated by levels of creatine kinase
(CK-MB, Figure 3A ) and troponin I (Figure 3B ) increased
upon reperfusion in both the DXS and PBS groups. The
release of CK-MB, and particularly troponin I, was more pro-
nounced in the PBS group. Inter-group difference, although
clearly visible, did not reach statistical signiﬁcance until the
end of the experiment after 2 h of reperfusion (P¼ 0.855 for
between-group differences, P¼ 0.256 for group–time inter-
action for CK-MB; P ¼ 0.410 for between-group differences,
P¼ 0.148 for group–time interaction for troponin I).
Infarct size
The myocardial AAR, expressed as percentage of the LVM,
was not signiﬁcantly different in the two groups (mean
39+ 8%/median 35.5% in PBS controls, mean 42+ 9%/
median 40.0% in DXS-treated animals; P ¼ 0.177,
Figure 3C ). Corresponding wet weights were 33.1+ 10.9
and 34.8+ 12.6 g, respectively. However, infarct size (NIT)
was signiﬁcantly lower in the DXS-treated animals when
compared with the PBS controls (NIT expressed as per cent
of AAR: 39+ 14%/38.4% vs. 61+ 12%/66.5%, P ¼ 0.003,
Figure 3D ). The respective wet weights were 12.6+ 4.8 g
in the DXS group and 19.9+ 6.5 g in the PBS controls.
Reduction of infarct size in space was not uniform in the
individual experiments. In four DXS experiments, ‘addi-
tional’ live tissue was distributed in a patchy fashion
within the area of necrosis, whereas in the other three
DXS experiments, infarct size reduction resulted from
retraction of infarct borders. An example of TTC staining
result with corresponding histology is shown in Figure 4.
Histology: infarct morphology
Typical signs of reperfusion damage with contraction bands
and coagulation necrosis were observed in the infarcted
area (NIT; Figure 4, right panel) from the DXS and PBS
groups, with no substantive differences between groups.
Gross haemorrhage was detected in one animal of each
group. Foci of microscopic haemorrhagic infarction were
equally detected in both groups (n ¼ 2 per group). Samples
from VIT (Figure 4, left panel) in both groups only focally
revealed minimal histological signs of ischaemia (wavy
ﬁbres). ANR samples showed normal histological ﬁndings.
Complement deposition, HSPG staining,
and TF expression
Figure 5 summarizes the data of complement deposition, HSPG
staining, and TF expression. Samples from all experiments
were stained and graded: 0¼ no staining, 1¼minimal focal
or diffuse staining, 2 ¼ moderately strong focal or diffuse
staining, 3 ¼ extensive focal or diffuse staining. Normal
tissue samples from healthy swine (not shown) and ANR
were used as controls.
Complement deposition (C1q, C4c, C3c/C3b, and C7) in
the NIT (in vasculature and on damaged myocytes) was
markedly decreased in the DXS-treated animals when com-
pared with PBS controls. Staining for complement deposition
was essentially negative in myocardium of healthy swine and
only traces of complement were detected in samples from
the ANR of both groups (Figure 6A ).
Ischaemic tissue, particularly NIT, showed less positivity
for HSPG staining when compared with non-ischaemic
samples. Inter-group differences were difﬁcult to detect,
as positive staining was not limited to vascular HSPG
(Figure 6B ).
Figure 2 No systemic inhibition of the classical complement pathway in either of the experimental groups as measured in CH50 test (A ). Transient inhibition of
the coagulation system with DXS, with aPTT prolongation at 5 min of reperfusion and normalization after 2 h of reperfusion. No prolongation of aPTT in the PBS
control group (B ). Data are mean + standard deviation.
Reperfusion injury and dextran sulfate 2337
TF expression was decreased in blood vessels within the
NIT from DXS-treated animals when compared with PBS con-
trols. In this latter group, upregulation of TF within the
injured vasculature (mainly endothelial surface) was associ-
ated with the infarct areas. Weak focal TF staining was
noted in select vessels obtained from the ANR and VIT,
with no differences between the two groups. Minimal
expression of TF was observed within native cardiac vascula-
ture of healthy swine (Figure 6C ).
Binding of DXS-Fluo
DXS-Fluo was used in four experiments to reveal adherence
of DXS to the tissue. Binding of DXS-Fluo was detected
speciﬁcally in the AAR (NIT and VIT regions) on the inner
lining of small and large blood vessels and focally in strongly
contracted myocytes (Figure 6D ). DXS-Fluo binding was
detected neither in the ANR of the heart nor in lungs,
liver, kidney, or spleen in any of the samples taken from
the four experiments.
Discussion
In the present study, we report that local, intracoronary
application of the glycosaminoglycan analogue DXS, just
Figure 3 Enzymatic infarct size measured by creatine kinase (CK-MB fraction) and troponin I (A and B ) in peripheral venous blood samples. Data are mean +
standard deviation. Ratios of AAR to LVM and NIT to AAR (C and D ). Individual values and medians (bars) are shown. AAR was comparable in both groups. DXS
treatment signiﬁcantly reduced infarct size when compared with PBS controls (mean 39+ 14%, median 38.4% with DXS, vs. 61+ 12%/66.5%, with PBS P ¼ 0.003).
Figure 4 TTC staining of representative section of left ventricle (PBS control
experiment) with corresponding histology from TTC red, viable ischaemic
tissue (VIT) and TTC unstained, necrotic ischaemic tissue (NIT). Haematoxylin–
eosin staining (scale bar: 50 mm).
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prior to reperfusion, can protect ischaemic vasculature,
as well as the surrounding myocardial tissue from the
consequences of reperfusion injury. This pharmacological
cardioprotection correlated directly with speciﬁc binding
of DXS-Fluo to ischaemically damaged vasculature and
surrounding myocardium.
Glycosaminoglycans and their analogues, such as heparin
and pentosan sulfate, have previously been used systemi-
cally to attenuate I/R injury. Non-anticoagulant N-acetyl
heparin and sulodexide, a mixture of glycosaminoglycans
with limited anticoagulant activity, proved as effective as
normal heparin.29,30 It may be complement inhibition
rather than systemic anticoagulation providing protection,
as well as the glycosaminoglycans’ ability to rapidly associ-
ate with the endothelium.31
Alterations of the endothelial glycocalyx have been
described to contribute to I/R injury,13,14 and inhibition of
these glycocalyx modiﬁcations by adenosine A2A receptor
activation attenuates tissue damage.15 From our own pre-
vious in vitro work, we know that DXS associates with endo-
thelial cells after cleavage of glycocalyx HSPGs by
heparinase, and that this binding correlates with comp-
lement inhibition.22 Presently, we could localize DXS
binding to ischaemically damaged blood vessels using DXS-
Fluo. This correlated with reduced vascular HSPG staining
observed in these areas.
Contribution of the complement system to myocardial
I/R injury has been documented early on.32 Inhibition of
the complement system with ﬂuid-phase33 or membrane-
targeted inhibitors34 has proved successful both in animal
models and in clinical settings.9,35 In our model, binding of
DXS within the ischaemic area correlated with attenuation
of deposition of C1q as well as C4b/c and C3b/c. C1q selec-
tively accumulates in ischaemic-reperfused myocardium,
concentrations correlating reciprocally with regional
myocardial blood ﬂow.36 Indeed, ﬁxation of C1q to subcellu-
lar fractions of myocardial cells, released upon ischaemic
damage, activates the complement cascade and stimulates
inﬁltration of polymorphonuclear leukocytes.37 However,
sequential activation and release of C5a, TGF-beta 1, and
MCP-1 may also promote myocardial healing following
reperfusion by monocyte recruitment.38 DXS also reduced
deposition of the terminal complement complex (TCC),
detected as C7. TCC may directly be involved in comp-
lement-induced injury in I/R,3 inhibition of its formation
possibly prove critical to preserving EC integrity. Whether
DXS, known to inhibit the lectin pathway in vitro,22 was
likewise inhibitory in this model is unclear, as antibodies
against porcine mannose-binding lectin (MBL) were not
available to us. A role for the lectin pathway in I/R injury
is emerging;39 selective inhibition of this pathway using
monoclonal antibodies against MBL has proved beneﬁcial in
myocardial I/R injury in rats.40 Whether attenuation of the
local pro-inﬂammatory environment pre-disposes to reduced
complement activation and tissue deposition or whether
complement inhibition precludes induction of vascular
inﬂammation remains to be studied.
Reperfusion damage not only renders the endothelium
pro-inﬂammatory, but also pro-coagulant. Healthy endo-
thelium maintains cell-surface anticoagulation by expressing
thrombomodulin41 and heparan sulfates, which enhance the
activity of TF pathway inhibitor and antithrombin.18,19
Figure 5 Grading of complement staining. Four samples per area and experiment were graded with respect to intensity for complement staining. Every point
represents the average of all evaluations for one experiment. Bars indicate median values. 0 ¼ essentially no staining, 1 ¼ minimal focal or diffuse staining, 2 ¼
moderately strong focal or diffuse staining, and 3 ¼ extensive diffuse staining [Saline controls (PBS, n ¼ 9) and DXS (n ¼ 7)].
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Figure 6 Effect of DXS treatment on deposition of complement on pig myocardium (A ). Staining for HSPG on pig myocardium (B ) and TF in myocardial blood
vessels (C ). Brown staining (black arrow) reveals TF expression, especially in PBS controls. Speciﬁc binding of DXS-Fluo to inner lining of blood vessels and focally
to strongly contracted myocytes in the infarcted area. No staining in blood vessels from the ANR (D ). All images are representative of at least four scored sections
per area (ANR, NIT, VIT) per experiment. Scale bars: 50 mm.
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Heparinase treatment abolishes this endothelial surface
property.42 Functionally replacing the shed HSPG layer by
a glycosaminoglycan analogue, such as DXS, may help
restore the essential property of ‘surface regulation’ of
the coagulation system. Successful cell surface-targeted
anticoagulation in systemic infection and inﬂammation has
been described recently.43 Here, the ability of surface-
bound DXS to modify the local pro-coagulant environment
and its effect on inhibition of TF upregulation was studied.
DXS treatment clearly decreased vascular TF expression
within the infarcted area when contrasted to PBS controls.
This suggests TF induction on vascular endothelium upon
reperfusion, or recruitment with the sequestration of
circulating microparticles,44 subsequent to exposure to
complement components, reactive oxygen species, and acti-
vated leukocytes. Exposure of TF on activated EC (and
monocyte/macrophages) to circulating coagulation factors
activates the extrinsic pathway of clotting via binding to
factor VII,45 generating a ﬁbrin clot. Limiting EC damage
and TF expression by DXS may be pivotal in reducing
tissue damage by attenuating intravascular thrombosis and
inﬂammation. Indeed, functional inhibition of TF with a
monoclonal anti-TF antibody or human recombinant,
active site-blocked activated factor VII, signiﬁcantly
reduced infarct size in rabbit models of MI.12,46
Intracoronary application of DXS also led to a transient
and mild inhibition of the ﬂuid-phase coagulation system
(aPTT prolongation). However, a therapeutically relevant
prolongation of aPTT was only observed immediately after
DXS injection, suggesting that ﬂuid-phase, systemic inhi-
bition of the coagulation system is of minor importance in
our model. Indeed, intracoronary infusion of fractionated
heparin, a glycosaminoglycan analogue with more potent
anticoagulant but lower complement-inhibitory properties
than DXS, did not reduce infarct size (n ¼ 2, results not
shown). On the contrary, infarcts were grossly haemorrhagic
and tissue exceedingly friable.
DXS did not signiﬁcantly affect haemodynamic parameters
within the observed reperfusion period. In models of myo-
cardial I/R injury, some authors describe beneﬁcial effects
on haemodynamics using complement inhibitors,47 whereas
others note no advantages.48 Clinical investigations imply
that early functional assessment after Q-wave myocardial
infarction has limited ability to predict recovery of ventricu-
lar function. Creatine kinase levels, however, were indepen-
dently predictive of recuperation of function.49 Within 2 h of
reperfusion, therefore, potentially favourable effects of DXS
on myocardial performance may still have been masked by
myocardial stunning.
Increasing clinical evidence suggests that time-to-treat-
ment signiﬁcantly determines post-MI outcome following
coronary intervention,50,51 conﬁrming results from animal
models, which show that duration of coronary occlusion is
a main determinant of infarct size.52,53 The contribution,
therefore, of reperfusion to irreversible cell injury
decreases with increasing ischaemia time. In our model,
the extent of irreversible cell damage after only 1 h ischae-
mia/2 h reperfusion is rather high. However, this is in
accordance with previously published work using pig
models.7,47 The near absence of collaterals in pigs may
explain such extensive necrosis.54 To study the effects of
DXS on reducing reperfusion-induced damage, we chose to
limit ischaemia time to 1 h. The effect of DXS or similar
substances in the clinical setting, although no less valuable,
may be less dramatic as long as time-to-treatment is not cut
back. Furthermore, treatment suitability of such substances
needs to be evaluated with more clinically applicable, com-
prehensive therapeutic intervention and longer follow-ups.
TTC staining, used to differentiate between viable and
necrotic tissue, allows sensitive and speciﬁc determination
of infarct size,55 but may require sufﬁcient reperfusion for
accurate assessment.56 Although propidium iodide may
prove more accurate for shorter reperfusion,57 it cannot dis-
criminate between areas of no reﬂow and viable myocar-
dium.56 TTC staining validity for 120 min reperfusion in
pigs has already been conﬁrmed, where viable TTC positive
islets within TTC negative necrotic tissue correlated with
electron microscopy ﬁndings.8
Our results support the hypothesis that cytoprotection by
DXS, targeted to an ischaemically altered and damaged
endothelium, can substantially decrease I/R injury. This
cytoprotection correlates with the association of DXS with
the damaged endothelium and reduced local complement
deposition. However, the mechanisms providing the bene-
ﬁcial effects in this model are likely to be multidimensional,
as the glycocalyx is crucial for endothelial function. Other
endothelium-related mechanisms such as protection against
myocardial oedema58 or inhibition of leukocyte adhesion59
may be involved. The exact nature of the protective
effect of DXS remains to be investigated in greater detail.
Nonetheless, we believe that the concept of targeted cyto-
protection of ischaemic tissue using substances such as DXS,
which locally modulate the pro-inﬂammatory and pro-
coagulant environment, may offer an attractive novel stra-
tegy for the development of a clinically signiﬁcant therapy
for reperfusion injury, complementing standard therapy.
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